期刊文献+

风湿性心脏病合并重度肺动脉高压的外科治疗 被引量:3

Surgical treatment for patients with rheumatic heart disease complicated with severe pulmonary artery hypertension
下载PDF
导出
摘要 目的观察风湿性心脏病合并重度肺动脉高压的外科治疗效果,总结围术期治疗经验。方法回顾性分析2010年1月至2016年12月74例在恩施土家族苗族自治州中心医院心胸外科行手术治疗的风湿性心脏病合并重度肺动脉高压(平均肺动脉压>50 mm Hg)患者的临床资料。Swan-Ganz漂浮导管监测术中、术后肺动脉压及阻力的变化,超声心动图检测术前、术后肺动脉压、左房内径、左室舒张末内径及射血分数,门诊随访评估患者心功能。结果 74例(8.5%)合并重度肺动脉高压的患者入选本研究。其中,男性32例(43.2%),年龄26~72岁,平均(48.6±16.4)岁,病程22.3±9.6年(16~35年),术中死亡6例(8.1%),Swan-Ganz漂浮导管监测术后即刻和24 h平均肺动脉压、肺血管阻力和肺毛细血管楔压较术前明显下降(均为P<0.05),心脏指数较术前明显升高(P<0.05)。复查超声心动图发现,左房内径明显缩小[(53.2±12.4)mm比(76.5±19.6)mm,P<0.001],左室射血分数明显增加[(54.7%±8.9%)比(46.3%±7.8%),P<0.01]。随访心功能明显改善(P<0.01)。亚组分析发现,高肺动脉压力(肺动脉压力>体循环平均动脉压)患者的术后早期肺动脉压、肺血管阻力和肺毛细血管楔压无明显下降,心脏指数无明显增加,手术死亡率明显增加[22.3%比3.6%,P<0.001]。但术后6个月复查超声心动图肺动脉压力较术前明显下降[(88.2±13.6)mm Hg比(52.1±8.7)mm Hg,P<0.01],心功能有明显改善。结论外科手术治疗可改善风湿性心脏病合并重度肺动脉高压患者的短期预后。但高肺动脉压患者的围术期死亡率高,需加强此类患者的围术期管理。
作者 向水 黄进启 黄宏灵 蔡彦力 郑勇 李旭 姚元波 Xiang Shui;Huang Jinqi;Huang Hongling;Cai Yanli;Zheng Yong;Li Xu;Yao Yuanbo(Department of Cardiothoracic Surgery, Central Hospital of Enshi Tujia and Miao Prefecture, Enshi 445000, Chin)
出处 《中国心血管杂志》 2018年第3期260-263,共4页 Chinese Journal of Cardiovascular Medicine
基金 湖北省自然科学基金指导性计划项目(2014CFC1065)~~
关键词 高血压 肺性 风湿性心脏病 外科手术 手术期间 Hypertension pulmonary Rheumatic heart disease Surgery Perioperative period
  • 相关文献

参考文献3

二级参考文献50

  • 1Ning Yin,Stephanie Kaestle,Jun Yin,Thomas Hentschel,Axel R. Pries,Hermann Kuppe,Wolfgang M. Kuebler.Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease[J]. Critical Care Medicine . 2009 (3)
  • 2Maya Guglin,Hammad Khan.Pulmonary Hypertension in Heart Failure[J]. Journal of Cardiac Failure . 2010 (6)
  • 3Carolyn S.P. Lam,Véronique L. Roger,Richard J. Rodeheffer,Barry A. Borlaug,Felicity T. Enders,Margaret M. Redfield.Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction[J]. Journal of the American College of Cardiology . 2009 (13)
  • 4Robert M. Califf,Kirkwood F. Adams,William J. McKenna,Mihai Gheorghiade,Barry F. Uretsky,Steven E. McNulty,Harald Darius,Kevin Schulman,Faiez Zannad,Eileen Handberg-Thurmond,Frank E. Harrell,William Wheeler,Jordi Soler-Soler,Karl Swedberg.??A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)(J)American Heart Journal . 1997 (1)
  • 5Carla A. Sueta,Mihai Gheorghiade,Kirkwood F. Adams,Robert C. Bourge,Srinivas Murali,Barry F. Uretsky,Marc R. Pritzker,Michael D. McGoon,Samuel M. Butman,Steven H. Grossman,James W. Crow,Christy L. Shaffer,Michael D. Thorn.??Safety and efficacy of epoprostenol in patients with severe congestive heart failure(J)The American Journal of Cardiology . 1995 (3)
  • 6Neal A. Chatterjee,Gregory D. Lewis.What Is the Prognostic Significance of Pulmonary Hypertension in Heart Failure?. CIRCULATION-HEART FAILURE . 2011
  • 7Houssaini, Amal,Abid, Shariq,Mouraret, Nathalie,Wan, Feng,Rideau, Dominique,Saker, Mirna,Marcos, Elisabeth,Tissot, Claire-Marie,Dubois-Rand?, Jean-Luc,Amsellem, Val?rie,Adnot, Serge.??Rapamycin Reverses Pulmonary Artery Smooth Muscle Cell Proliferation in Pulmonary Hypertension(J)American Journal of Respiratory Cell and Molecular Biology . 2013 (5)
  • 8Francesca Bursi,Sheila M. McNallan,Margaret M. Redfield,Vuyisile T. Nkomo,Carolyn S.P. Lam,Susan A. Weston,Ruoxiang Jiang,Véronique L. Roger.??Pulmonary Pressures and Death in Heart Failure(J)Journal of the American College of Cardiology . 2012 (3)
  • 9Amit Varma,Keyur B. Shah,Michael L. Hess.??Phosphodiesterase Inhibitors, Congestive Heart Failure, and Sudden Death: Time for Re‐Evaluation(J)Congestive Heart Failure . 2012 (4)
  • 10Marco Guazzi,Marco Vicenzi,Ross Arena,Maurizio D. Guazzi.??Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study(J)Circulation . 2011 (2)

共引文献18

同被引文献24

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部